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Letter to the editor: no increased febrile neutropenia risk
to cancer patients receiving lipegfilgrastim—correction
of a systematic review andmeta-analysis of randomized controlled
trials with G-CSF
W. Lehmacher1 & M. Klasser2 & A. Duering3
Reason
Wang et al. recently published a systematic review and meta-
analysis on the impact of primary prophylaxis (PP) with gran-
ulocyte colony-stimulating factors (G-CSF) on febrile neutro-
penia (FN) during chemotherapy [1]. In the article, the authors
state that Bover all chemotherapy cycles, there was a numeri-
cal but statistically nonsignificant increase in the FN risk for
lipegfilgrastim PP versus pegfilgrastim PP^ four times.
We would like to state that in our view, this claim is not
justified for the following three major reasons:
1. It is based on an indirect and mixed treatment compari-
sons although direct evidence is available from two recent
head-to-head randomized controlled trials (RCTs) show-
ing a compatible risk.
2. A non-significant result is not conclusive and does not
show evidence for the existence of an increase.
3. The indirect comparison has a poor validity because of
missing homogeneity, similarity, and consistency.
Contradiction
Ad 1) The study aimed to assess the G-CSF products admin-
istered as primary prophylaxis to cancer patients receiv-
ing myelosuppressive chemotherapy. A systematic lit-
erature review identified 27 publications (1990 to 2013)
representing 30 randomized, controlled trials evaluating
primary prophylaxis (PP) with filgrastim, pegfilgrastim,
lenograstim, or lipegfilgrastim in adults receiving mye-
losuppressive chemotherapy for solid tumors or non-
Hodgkin lymphoma (see Fig. 1). Direct, indirect, and
mixed treatment comparison (MTC) were used to esti-
mate the odds ratio (OR) of febrile neutropenia (FN)
during cycle 1 and all cycles of chemotherapy com-
bined without adjusting for differences in relative dose
intensity (RDI) between study treatment arms.
It becomes apparent from Fig. 1 that there were
two head-to-head studies comparing directly
lipegfilgrastim with pegfilgrastim [2, 3] including a
total of 306 patients.
The results of the meta-analysis for this direct
comparison are shown in Fig. 2; seven events of
FN occurred in each treatment group. The odds ratio
for the Bcombined view^ is 0.98.
Table 1 shows the posterior odds ratios for FN
from all cycles with and without the assumption of
consistency.
The OR for the direct comparison is 1.00 (indicating
equal risks for FN by lipegfilgrastim and pegfilgrastim).
The result of the Bindirect comparison^ is completely
different, OR = 2.00, seemingly indicating an
Bincreased^ risk for FN by lipegfilgrastim. The result
of the combination of direct and indirect comparison
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Fig. 1 Overview of data from
RCTs on G-CSF PP included in
meta-analysis
Fig. 2 Meta-analysis comparing directly lipegfilgrastim with pegfilgrastim
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Which approach is providing the best evidence?
The Cochrane Handbook for Systematic Reviews of
Interventions [4] states: BIn situations when both direct
and indirect comparisons are available in a review, then
unless there are design flaps in the head-to-head trials,
the two approaches should be considered separately and
the direct comparison should take precedence as a basis
of forming conclusions.^
Leading institutions for health technology assess-
ment (HTA) such as the Canadian Agency for Drugs
and Technologies in Health (CADTH) [5], the National
Institute for Health and Clinical Excellence (NICE),
London [6] and the German Institute for Quality and
Efficiency in Health Care (IQWiG), and Cologne [7]
have a clear recommendation for this situation:
& They have a preference for data from head-to-head
RCTs.
& Evidence from mixed treatment analyses may be pre-
sented if it is considered to add information.
& If data from head-to-head RCTs are not available,
indirect treatment comparison methods may be used.
Many methodological questions for MTCs still
remain to be answered [8]. In a current review,
Song et al. [9] describe that significant differences
between results from indirect and direct comparisons
occur more frequently than previously assumed.
Due to the high risk of biased results and the nu-
merous unresolved methodological problems, in
general, no certain proof of benefit of a medical
intervention can currently be inferred from results
of indirect comparisons.
Therefore, claiming a non-significant numerical
higher risk for FN for lipegfilgrastim compared to
pegfilgrastim is not sustainable. There were a total
of 7:7 events of FN in both head-to-head studies
together, but an indirect OR of 2.0 indicates that
the application of inconsistent indirect or mixed
methods is not only unnecessary but leads to poten-
tially biased risk estimates.
Ad 2) Results from clinical studies may be conclusive only if
hypothesis testing leads to statistically significant results.
Therefore, it is impossible to claim a Bnumerical
difference^ in favor of a group without statistical signif-
icance. For example, in the head-to-head studies against
pegfilgrastim, lipegfilgrastim showed Bnumerical but
not statistically significant^ superiority in several other
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Table 1 Posterior odds ratios for febrile neutropenia from all cycles













1.00 (0.26–3.79) 2.00 (0.47–8.11) 0.76 1.39 (0.54–3.50)
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efficacy parameters. So far, such advantages have not
been claimed, due to statistical non-significance.
Ad 3) The indirect comparison itself lacks validity: the meta-
analysis of five studies comparing pegfilgrastim vs.
placebo shows a strong heterogeneity due to the oldest
study (Vogel et al. [10]). The meta-analysis of the
pegfilgrastim studies shows a total event rate of
15.1 % in the control group, whereas the
lipegfilgrastim studies have a total event rate of 8 %.
This shows a strong dissimilarity in the types of pa-
tients included which could be the reason for the in-
consistency between direct and indirect comparison.
Conclusion
It is not justified to claim a numerical difference in favor of
a specific treatment based on non-significant study results.
The result of a mixed treatment comparison with poor va-
lidity is less reliable than the evidence from available direct
comparison. Thus, the FN risk for lipegfilgrastim PP rela-
tive to pegfilgrastim PP is comparable.
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